Table 3.
PANSS Symptomatic Remission During Open-Label Extension
| Remission Statusa n (%) |
PP3M/PP6M (n = 57) |
PP6M/PP6M (n = 121) |
Total (N = 178) |
|---|---|---|---|
| Month 12 | |||
| No | 13 (23.2) | 19 (16.2) | 32 (18.5) |
| Yes | 43 (76.8) | 98 (83.8) | 141(81.5) |
| Month 24 | |||
| No | 10 (18.9) | 14 (13.9) | 24 (15.6) |
| Yes | 43 (81.1) | 87 (86.1) | 130 (84.4) |
| Endpoint | |||
| No | 10 (17.9) | 18 (15.4) | 28 (16.2) |
| Yes | 46 (82.1) | 99 (84.6) | 145 (83.8) |
Abbreviations: PANSS, Positive and Negative Symptom Scale; PP3M, paliperidone palmitate 3-month formulation; PP6M, paliperidone palmitate 6-month formulation.
aRemission is defined as having a score ≤3 on all these PANSS items: P1, P2, P3, N1, N4, N6, G5, and G9.